BillionToOne

One week left to register for UNITY's upcoming webinar! Where others stop, we keep going. Advancing fetal risk assessment with QCT technology. Hear from the experts and register here ➡️ https://lnkd.in/ej2xtxBq #UNITYComplete #wekeepgoing #QCTtechnology

🎉 Big news! BillionToOne has officially reached 1 million UNITY prenatal tests—a huge milestone in making our prenatal testing more accessible! Our Co-Founder & CEO, Oguzhan Atay, PhD, shares how our QCT technology is transforming prenatal care and beyond. With an annual run rate of 500k+ tests, we’re just getting started in redefining diagnostics for both prenatal and oncology care. A huge thank you to everyone helping us push the boundaries of what’s possible. This couldn't have been done without the support of our partners and providers, and of course all the employees at BillionToOne! Read more here ➡️ https://lnkd.in/e6NdYmWi #1MillionTests #FutureOfDiagnostics

UNITY is exhibiting at the Medical University of South Carolina's 54th Annual OBGYN Spring Symposium this week in Charleston, SC! We're excited to be attending this conference that provides engaging, evidence-based updates on a range of obstetrical and gynecological challenges and finding ways to improve the quality of care for patients. We would love to see you at our table today and tomorrow to discuss how UNITY is setting the new standard in prenatal care. Find more event information here ➡️ https://lnkd.in/emfPjiyz #UNITY #MUSC #prenatalcare

Join UNITY for our upcoming webinar on the groundbreaking advancements in fetal risk assessment using BillionToOne's proprietary Quantitative Counting Template™ technology. Discover how QCTs power UNITY Complete® and are transforming how we assess fetal risk for recessive single-gene disorders and fetal antigen status with cfDNA. Hear from the experts and register here ➡️ https://lnkd.in/ej2xtxBq #QCTtechnology #UNITYComplete #wekeepgoing

📣 BillionToOne has been recognized on Forbes’ list of America’s Best Startup Employers for 2024! A very timely award for Employee Appreciation Day! At BillionToOne, we’re driven by a mission to create powerful and accurate tests that are accessible to all. But what truly sets us apart is our incredible team—a group of passionate, innovative, and dedicated individuals who push the boundaries of what’s possible every day. Being named one of the best startup employers is a testament to the culture we’ve built—one that values collaboration, growth, and making a real difference in patients' lives. A huge thank you to our employees who make this company what it is. We couldn’t do it without you! See the full list here ➡️ https://lnkd.in/dGSX3ahr #Forbes #BestStartupEmployers #TeamBillionToOne #WeKeepGoing

 ⭐ Happy Employee Appreciation Day ⭐  Today, we celebrate the exceptional talent and dedication of our team that drives innovation in molecular diagnostics. Your passion transforms complex science into clarity for patients in need. Each of you plays a vital role in delivering peace of mind—behind every result is a story, a family waiting for answers. Thank you to our team at BillionToOne! We appreciate everything you do! #EmployeeAppreciation #TeamWork #MolecularDiagnostics

In cancer care, true quantification in treatment response monitoring has been missing—until now. A newly published peer-reviewed study in Nature Scientific Reports further validates Northstar Response®, our tissue-free ctDNA liquid biopsy, as a precise and convenient tool for monitoring treatment response in Stage III-IV cancers across multiple tumor types. Powered by proprietary QCT™ technology, Northstar Response enables up to 10x more precise treatment response monitoring than alternative blood-based methods, offering a pan-cancer, non-invasive solution for clinicians. Find out what this means for oncology care—full details in the comments. #MolecularDiagnostics #OncologyResearch #CancerCare #LiquidBiopsy #QCTtechnology #NorthstarResponse #BillionToOne

We’re excited to share that our latest clinical study, published in the Green Journal, demonstrates 100% accuracy in non-invasive fetal RhD detection using our QCT™ technology! This study underscores our commitment to advancing prenatal care, offering a critical solution for RhD-negative individuals, and ensuring accurate testing across diverse populations. Read the full press release to learn more ➡️ https://lnkd.in/e6VnCBU8 #MolecularDiagnostics #PrenatalTesting #InnovationInHealthcare #MenloPark #BillionToOne #QCTtechnology

Hello Houston! UNITY will be at the Houston Gynecological Obstetrics Society's February Meeting today. We look forward to meeting you at dinner and discussing how UNITY is the new standard in prenatal care! #UNITY #HGOS #prenatalcare Jessica Lutrick, Jennifer Macdonel, Maria Herman Alvarez

The BillionToOne Biopharma Solutions team is at #LiquidBiopsy for Precision Oncology Summit in San Diego! Don’t miss Co-Founder & Chief Technology Officer Dr. David Tsao present how BillionToOne’s patented QCT™ technology achieves single molecular resolution and powers our Northstar Select® and Northstar Response® ctDNA assays. Learn more here: https://lnkd.in/eG87nC7z #liquidbiopsy, #LBxSummit Matthew Varga, PhD, Ezequiel Renzulli